UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM SD
SPECIALIZED DISCLOSURE REPORT
GlaxoSmithKline plc
(Exact name of Registrant as specified in its charter)
| England and Wales | | 001-15170 | | 98-0607772 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
GlaxoSmithKline plc
980 Great West Road
Brentford, TW8 9GS
England
(Address of principal executive offices)
Victoria Whyte
Company Secretary
+44 20 8047 5000
(Name and telephone number of this person to contact in connection with this report)
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
☒ Rule 13p-l under the Securities Exchange Act (17 CFR240.13p-l) for the reporting period from January 1 to December 31, 2018.
Section 1 – Conflict Minerals Disclosure
| Item 1.01 | Conflict Minerals Disclosure and Report |
The Conflict Minerals Report for GlaxoSmithKline plc (GSK) for the year ended December 31, 2018 is attached as Exhibit 1.01 to this Report and is available on GSK’s website at https://www.gsk.com/en-gb/about-us/policies-codes-and-standards/.
GSK’s Conflict Minerals Report is attached as Exhibit 1.01 to this Report.
Section 2 – Exhibits
The following exhibit is filed as a part of this report.
| Conflict Minerals Report for the Year Ended December 31, 2018 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
| |
| /s/ Iain MacKay | |
| Dated: May 31, 2019 | Name: Iain MacKay | |
| | Title: Chief Financial OfficerGlaxoSmithKline plc | |
3
